





Have Questions?



Type them into questions box!

“Why am I muted?”

Don't worry. Everyone is muted except the presenter and host. Thank you and enjoy the show.

Contact ACS Webinars® at acswebinars@acs.org

1



ACS membership means ...

THE MOST TRUSTED
science at your fingertips.

Click to learn more

<http://bit.ly/ACSnewmember>

2



Benefits of ACS Membership



Weekly subscription to ACS's chemical news magazine, delivered in print or online



25 free activities through the CAS® (Chemical Abstracts Service)



50 free articles per year from the most trusted and cited collection of scientific publications in the world



Exclusive access the first two weeks of any job posting

<http://bit.ly/ACSnewmember>

3



@AmericanChemicalSociety



@AmerChemSociety



@AmerChemSociety



<https://www.linkedin.com/company/american-chemical-society>

Contact ACS Webinars® at acswebinars@acs.org

4

How has ACS Webinars[®] benefited you?



“This ACS Webinar was informative about the benefits of using paper and hazards of plastics. Great to know what strides the paper industry is taking to recycle and the rates of recycling. Very impressive and encouraging!”

Fan of the Week

Jeanne Shoulder
QC Manager, DSM Nutritional Products
ACS member 7 years strong!

Is **paper** and **pulp** recycling the solution to our **single-use** package problem?

<https://www.acs.org/content/acs/en/acs-webinars/technology-innovation/paper/video.html>

OPEN ACCESS RECORDING!

Be a featured fan on an upcoming webinar! Write to us @ acswebinars@acs.org

5



ACS Webinars[®]

CLICK • WATCH • LEARN • DISCUSS

LIVE | Thursdays at 2pm ET



Learn from the best and brightest minds in chemistry! Hundreds of webinars on diverse topics presented by experts in the chemical sciences and enterprise.

Recordings are an exclusive ACS member benefit and are made available to registrants via an email invitation once the recording has been edited and posted.

Live Broadcasts of ACS Webinars[®] continue to be available to the general public on Thursdays from 2-3pm ET!

www.acs.org/acswebinars

6

What is ACS on Campus?



ACS visits campuses across the world offering FREE seminars on how to be published, find a job, network and use essential tools like SciFinder. ACS on Campus presents seminars and workshops focused on how to:



- Publish in top journals
- Find a job
- Effectively use research tools like SciFinder® and ACS ChemWorx
- Communicate your science
- Write grant proposals
- Build industry partnerships
- Prepare for a changing employment landscape


<http://acsoncampus.acs.org>

7

#HeroesofChemistry ACS Heroes of Chemistry Award



Inspiring Hero Stories



[View All Past Recipients >>](#)

The ACS Heroes of Chemistry Award is the Annual award sponsored by the American Chemical Society that recognizes talented industrial chemical scientists whose work has led to the development of successful commercialized products ingrained with chemistry for the benefit of humankind.


2018 Winners:



www.acs.org/heroes

8

An individual development
planning tool for you!



<https://chemidp.acs.org>

9

Upcoming ACS Webinar
www.acs.org/acswebinars



RECENT DEVELOPMENTS in PATENT LAW

ACS Technical Division Chemistry & the Law (CHAL) ACS Chemistry for Life

NON-OBVIOUSNESS OF CHEMICAL AND PHARMACEUTICAL FORMULATION PATENTS

▶ **FREE** | Thursday, July 18 at 2pm ET

ACS Webinars

<https://www.acs.org/content/acs/en/acs-webinars/business-entrepreneurship/non-obviousness.html>

10

The ACS Green Chemistry Institute Pharmaceutical Roundtable (ACS GCIPR) Advancing Research!




- The ACS GCIPR has identified key synthetic chemistry and process research challenges whose solutions would result in more efficient pharmaceutical process development and production.

<https://www.acsgcpr.org>

11

ACS GCIPR: A Decade of Funding!



ORGANIC PROCESS RESEARCH & DEVELOPMENT
OPR&D

Evaluating the Impact of a Decade of Funding from the Green Chemistry Institute Pharmaceutical Roundtable

Stefan G. Koenig David K. Leahy and Andrew S. Wells

<https://pubs.acs.org/doi/10.1021/acs.oprd.8b00237>

- To date, 28 research programs have been funded globally on topics such as C–H activation, flow chemistry, biocatalysis, novel catalytic transformations, base metal catalysis, and solvent substitution. From these research projects, 73 peer-reviewed publications have resulted with over 1700 unique daughter citations.

<https://www.acsgcpr.org>

12

Proudly Co-produced with **ACS Green Chemistry Institute**




THIS ACS WEBINAR WILL BEGIN SHORTLY...

13



Slimming the Waste-line in Large Molecule Syntheses



Slides available now! Recordings are an exclusive ACS member benefit.

www.acs.org/acswebinars

This ACS Webinar is co-produced with the ACS Green Chemistry Institute

14

Slimming the Waste-line in Large Molecule Syntheses

Dr. Michael E. Kopach, Dr. Ben Andrews, Dr. Albert Isidro Llobet and Dr. Isamir Martinez

ACS Webinar
July 11, 2019

© 2015 Eli Lilly and Company


Lilly



Green Chemistry

Green Chemistry and sustainable science is the strategic design, development, and implementation of chemical products and processes that reduce or eliminate the use and generation of hazardous substances and waste, are inherently safe, and increase efficiency while minimizing environmental footprint and impact.

Good science is the key to sustainability, green chemistry, and low cost manufacturing across the globe.



Noyori - "...green chemistry is not just a catchphrase. It is an indispensable principle of chemical research that will sustain our civilized society in the twenty-first century and further into the future."^{*1}

Tucker - "...a privileged opportunity for innovation" representing "an emerging new frontier of exploration."^{*2}

If industry focuses on developing the best chemistry, then almost always this leads to the lowest costs and greenest processes.

^{*1} Noyori, R. "Synthesizing our future." *Nature Chemistry* **2009**, 1, 5-6.


^{*2} Tucker, J.L. "Green Chemistry, a Pharmaceutical Perspective." *Org. Process Res. Dev.* **2006**, 10(2), 315-319.



Business Case for Green Chemistry

- pharmaceutical & generics industries may produce ≥ 100 million kg APIs per year ^{*1}
- cEF ≥ 150 kg waste per kg API ($> 99.3\%$) $\rightarrow \geq 15$ billion kg of co-produced waste
- annual waste disposal cost of $\sim \$30$ billion **€\$£¥**

opportunity for industry to utilize **green chemistry** to trim both process inputs and waste, and **create \$ billions in economic, environmental, and social value**



^{*1} B. W. Cue, (2012) Green Chemistry Strategies for Medicinal Chemists, in Green Techniques for Organic Synthesis and Medicinal Chemistry (eds. Zhang, W., and Cue, B. W.). John Wiley & Sons,

Audience Survey Question

ANSWER THE QUESTION ON BLUE SCREEN IN ONE MOMENT



A majority of the top 10 selling pharmaceuticals in 2018 were:

(More than one correct answer may exist)

- Large Biomolecules ($> 10,000$ AMU)
- Small Molecules (< 500 AMU)
- Cancer Drugs
- Diabetes Drugs

** If your answer differs greatly from the choices above tell us in the chat!*



2018 Top Selling Pharmaceuticals

Medication	Pharmaceutical Company	Total Sales	U.S. Sales	Modality	Indication
1. Humira (Adalimumab)	AbbVie	\$19.9 billion	\$13.7 billion	Large	Rheumatic Diseases and Inflammatory Bowel Disease
2. Eliquis (Apixaban)	Bristol-Myers Squibb/Pfizer	\$9.87 billion	\$5.61 billion	Small	Anticoagulant (Blood Thinner) for Heart Arrhythmias
3. Revlimid (Lenalidomide)	Celgene	\$9.69 billion	\$6.47 billion	Small	Multiple Myeloma
4. Keytruda (Pembrolizumab)	Merck	\$7.17 billion	\$4.15 billion	Large	Cancer Chemotherapy
5. Enbrel (Etanercept)	Amgen/Pfizer	\$7.13 billion	\$4.81 billion	Large	Rheumatic Diseases
6. Herceptin (Trastuzumab)	Roche	\$6.84 billion	\$2.85 billion	Large	Breast Cancer Chemotherapy
7. Eylea (Aflibercept)	Regeneron	\$6.75 billion	\$4.08 billion	Large	Wet Macular Degeneration
8. Opdivo (Nivolumab)	Bristol-Myers Squibb	\$6.74 billion	\$4.24 billion	Large	Cancer Chemotherapy
9. Avastin (Bevacizumab)	Roche	\$6.71 billion	\$2.85 billion	Large	Cancer Chemotherapy
10. Rituxin (Rituximab)	Roche	\$6.62 billion	\$4.20 billion	Large	Rheumatic Diseases and Cancer Chemotherapy


8 out of 10 are large molecules and 6 out of 10 have cancer related indications



19



Complexity




20



Oligonucleotide and Peptide Products


Oligonucleotide



Nucleic Acid Building Blocks

Peptide

Peptide = chain of amino acids



Amino Acid Building Blocks

- Solid Phase Synthesis and Chromatographic Purification are Common to both Platforms

Audience Survey Question

ANSWER THE QUESTION ON BLUE SCREEN IN ONE MOMENT



In 1901 which transformative scientific discovery(s) were made?

(More than one correct answer may exist)

- Robert Merrifield invents solid phase peptide synthesis
- Emil Fischer discovers first synthetic peptide
- Victor Grignard discovers the Grignard Reaction
- None of the above


** If your answer differs greatly from the choices above tell us in the chat!*



Peptide Overview

Peptides have been around since insulin in the 1920s.

Once solid phase peptide synthesis was introduced by Merrifield in 1963 they dramatically increased in popularity and complexity as production was feasible.






Lau et al. *Bioorganic & Medicinal Chemistry*. 26 (2018) 2700-2707

ACS Green Chemistry Institute
Pharmaceutical Roundtable 23



Examples of Increasing Peptide Complexity


Natural incretins:




ACS Green Chemistry Institute
Pharmaceutical Roundtable 24



Oligonucleotide and Peptide SPS



Common Large Molecule Processes




- Excludes Synthetic Peptides and Oligonucleotides

<https://www.sciencedirect.com/science/article/pii/S1871678418302255>




Water For Injection Processes



Budzinski et. al. *New Biotechnology* Volume 49, 25 March 2019, Pages 37-42.




12 Principles of Green Chemistry



P. T. Anastas & J. C. Warner, *Green Chemistry: Theory and Practice*, Oxford University Press: New York, 1998.



12 Principles of Green Peptides



P. T. Anastas & J. C. Warner, *Green Chemistry: Theory and Practice*, Oxford University Press: New York, 1998.







ACS Green Chemistry Institute
Pharmaceutical Roundtable

29



2019 ACS Green Chemistry Institute Pharmaceutical Roundtable

 <p>Tools for Innovation in Chemistry</p> <p>Solvent Selection Reagent Guides PMI-LCA & PMI Prediction MedChem Tips & Tricks</p>	 <p>Advancing Research</p> <p>Key Research Areas Research Grants Journal Publications Impact</p>	<p>Current Members</p> <p>AbbVie Amgen AstraZeneca Bayer Biogen Boehringer Ingelheim Bristol-Myers Squibb Eli Lilly and Company F. Hoffmann-La Roche Ltd. Gilead GlaxoSmithKline Ipsen Johnson & Johnson Merck & Co., Inc Neurocrine Novartis Novo Nordisk Pfizer, Inc. Sanofi Takeda Vertex ACS Green Chemistry Institute®</p>
 <p>Educating Leaders</p> <p>Chem21 Training Workshops Presentations Awards</p>	 <p>Global Collaboration</p> <p>India China PSCI & IQ Benchmarking</p>	

- Pre-Competitive Consortium Founded in 2005 by Merck, Lilly and Pfizer
- Catalyzing the integration of green chemistry and engineering in the pharmaceutical industry

<https://www.acsgcpr.org>



ACS Green Chemistry Institute
Pharmaceutical Roundtable

30



2019 ACS Green Chemistry Institute Pharmaceutical Roundtable



abbvie

AMGEN

AstraZeneca

Bayer HealthCare
Pharmaceuticals

Bristol-Myers Squibb

Biogen

Boehringer
Ingelheim

GILEAD

gsk

IPSEN

Johnson & Johnson

Lilly

MERCK

Neurocrine
BIOSCIENCES

novo nordisk

NOVARTIS

Roche
Genentech
A Member of the Roche Group

Pfizer

SANOFI

Takeda

ucb

VERTEX

AMPAC™
FINE CHEMICALS

ASYM-CHEM

HIKAL

BACHEM

CODEXIS

I-N-N-O
S-Y-N
Tomorrow's chemistry. Today.

康龙化成
PHARMARON

WuXi AppTec

CORTEVA™
agriscience
Agriculture Division of DowDuPont™

ACS Green Chemistry Institute
Pharmaceutical Roundtable

31



Pharma Roundtable Key Research Areas

753 Citations

- ***2007 KRA Manuscript:** *Green Chem.*, 2007,9, 411-420

Key green chemistry research areas—a perspective from pharmaceutical manufacturers

David J. C. Constable,^a Peter J. Dunn,^{a,b} John D. Hayler,^c Guy R. Humphrey,^d Johnnie L. Leazer, Jr.,^e Russell J. Linderman,^f Kurt Lorenz,^g Julie Manley,^h Bruce A. Pearlman,^h Andrew Wells,ⁱ Aleksey Zaks^h and Tony Y. Zhang^g

Received 7th March 2007, Accepted 26th March 2007
First published as an Advance Article on the web 17th April 2007
DOI: 10.1039/b603488g

In 2005, the ACS Green Chemistry Institute (GCI) and the global pharmaceutical corporations developed the ACS GCI Pharmaceutical Roundtable to encourage the integration of green chemistry and green engineering into the pharmaceutical industry. The Roundtable has developed a list of key research areas. The purpose of this perspective is to summarise how that list was agreed, provide an assessment of the current state of the art in those areas and to highlight areas for future improvement.

- **2018 KRA Manuscript:** *Green Chem.*, 2018,20, 5082-5103.

Key Green Chemistry research areas from a pharmaceutical manufacturers' perspective revisited

Check for updates

Marzen C. Bryan,^a Peter J. Dunn,^b David Emrysle,^c Fabrice Gallou,^d Stefan G. Hoering,^e John D. Hayler,^{af} Matthew R. Hickey,^{ag} Shaun Hurlbut,^{ah} Mirhaek E. Kojach,^{ai} Gerard Morris,^{aj} Paul Richardson,^{ak} Frank Roschangar,^{al} Alan Stevens^{am} and Franz J. Welbert^{an}

Author affiliations




ACS Green Chemistry Institute
Pharmaceutical Roundtable

32



Overview: Pharma Key Research Areas

- Inexpensive /**sustainable metals** methodologies
- Sustainable catalysis for (direct) **amide or peptide formation**
- **Green oxidants** aliphatic and aromatic **C–H activation**
- **Amide reductions** avoiding LiAlH_4 and diborane
- Direct **substitution of alcohols**
- **Catalyst immobilization** (no loss of kinetics)
- **Asymmetric hydrogenation** of unfunctionalized olefins/ enamines/imines
- Improved **fluorination/trifluoromethoxylation**
- **Wittig chemistry** without Ph_3PO
- **Alternatives for oxidations**, C–O or C–N redox processes
- **Polar aprotic solvents** replacements
- **Halogenated solvents** replacements



acsgcipr.org

Green Chem., **2018**, *20*, 5082. DOI: 10.1039/C8GC01276H

ACS Green Chemistry Institute
Pharmaceutical Roundtable

33



Pharma RT 2025 Strategic Priorities



MISSION

catalyze GC&E
in the global
pharmaceutical
industry

- Peptides and Oligos Relatively New Team founded in 2016
- **Charter:** To educate and influence today's and tomorrow's scientists and industries in the business value and scientific merit to utilize green chemistry and engineering principles to guide development and manufacture of peptide, oligonucleotide products.

ACS Green Chemistry Institute
Pharmaceutical Roundtable

34



ACS GCI Peptide and Oligo Subteams

AstraZeneca Louis Diorazio, Anna Watson, and Martin Kenworthy

Biogen Firoz Antia

Boehringer Ingelheim Heewon Lee

Bristol-Myers Squibb Shawn Brueggemeier and Subha Mukherjee

gsk Ben Andrews* and Albert Isidro Llobet**

Lilly Michael Kopach

Roche Martin Olbrich

IPSEN Katrzyna Wegner

NOVARTIS Fabrice Gallou

AMGEN Austin Smith

ACS Green Chemistry Institute Isamir Martinez

*Oligonucleotide Team Lead

** Peptide Team Lead

ACS Green Chemistry Institute
Pharmaceutical Roundtable

35



Solid Phase Peptide Synthesis


Advantages:

- ✓ Proven technology
- ✓ Efficient method of production for short sequences
- ✓ Accepted current practice

Challenges:

- ✓ Solvent intensive process
- ✓ Yield and purity significantly decrease as peptide length increases
- ✓ Addition and deletion (and analog) impurities are possible and propagate
- ✓ Up to 20% risk of total loss increases as a function of peptide length*

Yield versus Fragment Length Assumption



ACS Green Chemistry Institute
Pharmaceutical Roundtable


36



Pharma RT Peptide Key Research Areas

Sustainability challenges in peptide synthesis and purification: from R&D to production

Albert Isidro-Llobet,^{a*} Martin N. Kenworthy,^b Subha Mukherjee,^c Michael E. Kopach,^d
Katarzyna Wegner,^e Fabrice Gallou,^f Austin G. Smith,^g Frank Roschangar^h



- (1) **Convergent** hybrid synthesis
- (2) **Greener solvent** choices
- (3) Improved **resins/recycling**
- (4) Unprotected peptide **ligation**
- (5) Peptide synthesis in **flow**
- (6) **Greener separation** technologies
- (7) Innovation to **reduce PMI**

Sustainability Aspirations
←
Call to Innovation

- (1) **Linear** synthesis
- (2) Heavy **toxic solvent** usage
- (3) Poor **resin loading**
- (4) **Protecting group** usage
- (5) **Batch** synthesis
- (6) Intensive **chromatography**
- (7) **High PMI**

<https://pubs.acs.org/doi/10.1021/acs.joc.8b03001> *J. Org. Chem.*, 2019, 84 (8), pp 4615–4628



ACS Green Chemistry Institute
Pharmaceutical Roundtable


37



Tools to Make Processes Greener

Family	Solvent	BP (°C)	FP (°C)	Water solubility	Safety score	Health score	Env. score	Shading by default	Ranking from the survey
Water	Water	100	0	soluble	5	5	5	Recommended	Recommended
	EtOH	78	11	soluble	4	4	4	Recommended	Recommended
	n-PrOH	97	12	soluble	3	3	3	Recommended	Recommended
Alcohols	i-PrOH	82	12	soluble	3	3	3	Recommended	Recommended
	n-BuOH	117	20	soluble	2	2	2	Recommended	Recommended
	t-BuOH	82	25	soluble	2	2	2	Recommended	Recommended
Ethers	EtOAc	77	-4	soluble	3	3	3	Recommended	Recommended
	n-BuOAc	89	2	soluble	2	2	2	Recommended	Recommended
	t-BuOAc	118	22	soluble	2	2	2	Recommended	Recommended
Ethers	Dioxane	101	-17	soluble	1	1	1	Not recommended	Not recommended
	Diisopropyl ether	69	-28	soluble	2	2	2	Not recommended	Not recommended
	MeTHF	40	-11	soluble	2	2	2	Not recommended	Not recommended
Hydrocarbons	LA-Dioxane	101	12	soluble	1	1	1	Not recommended	Not recommended
	Acetone	56	5	soluble	2	2	2	Not recommended	Not recommended
	DMF	29	-28	soluble	1	1	1	Not recommended	Not recommended
Hydrocarbons	Hexane	69	-95	soluble	1	1	1	Not recommended	Not recommended
	Heptane	98	-91	soluble	1	1	1	Not recommended	Not recommended
	Octane	126	-89	soluble	1	1	1	Not recommended	Not recommended
Hydrocarbons	Me-Cyclohexane	101	-4	soluble	1	1	1	Not recommended	Not recommended
	Hexane	69	-95	soluble	1	1	1	Not recommended	Not recommended
	Toluene	111	4	soluble	1	1	1	Not recommended	Not recommended
Hydrocarbons	Hexane	69	-95	soluble	1	1	1	Not recommended	Not recommended
	Heptane	98	-91	soluble	1	1	1	Not recommended	Not recommended
	Octane	126	-89	soluble	1	1	1	Not recommended	Not recommended

Solvent Guides:
77 solvents; 3 criteria: safety, health, environment



Solvent Interactive Tool:
272 solvents / selection based on physical properties, functional groups and environmental data.

The reagent guides purpose is to encourage chemists to choose a 'greener' choice of reaction conditions. The guides aim to achieve this by providing transparency through the use of Venn diagrams in addition to improving understanding by discussion and up to date references.

The Reagent Guides

Select the chemical transformation of interest.

[VIEW](#)


How to Interpret the Venn Diagrams

[VIEW](#)

Edges of the Reagent Guides

Understand the purpose behind the construction of the guides.

[VIEW](#)



Reagent Guides: reagentguides.com

18 guides, > 150 reagents, citation links

Coming soon!

Amide bond reagent guide specific to polypeptides

acsgepr.org



ACS Green Chemistry Institute
Pharmaceutical Roundtable

38



Key 2018 Novartis Contribution

■ *N*-Butylpyrrolidinone as Alternative Solvent for Solid-Phase Peptide Synthesis


John Lopez, Stefan Pletscher, Andreas Aemissegger, Christoph Bucher, and Fabrice Gallou

Org. Process Res. Dev., 2018, 22 (4), pp 494-503

Publication Date (Web): March 14, 2018 (Article)

DOI: 10.1021/acs.oprd.7b00389

By means of a systematic approach, several green solvent candidates were tested for their feasibility to replace the reprotoxic dimethylformamide (DMF) as a solvent used in solid-phase peptide synthesis (SPPS). According to the results presented in this ...



ACS Green Chemistry Institute
Pharmaceutical Roundtable

39



Peptide Research Grant: Professor Jennifer Stockdill

Bringing Macrolactamization Full Circle: Self-Cleaving Head-to-Tail Macrocyclization of Unprotected Peptides via Mild *N*-Acyl Urea Activation

Christine A. Arbour,^a Kayla J. Belavek,^a Rooha Tariq,^b Subha Mukherjee,^b Janine K. Tom,^c Albert Isidro-Llobet,^d Michael E. Kopach,^a and Jennifer L. Stockdill^{a*}

^aDepartment of Chemistry, Wayne State University, Detroit, MI, USA 48202

^bBristol-Myers Squibb, Chemical and Synthetic Development, New Brunswick, NJ, 08903, USA


^cAmgen, Inc.

^dGlaxoSmithKline, Medicines Research Centre, Stevenage SG1 2NY, UK

^eEli Lilly and Company, Indianapolis, IN, 46285, USA

Supporting Information Placeholder

ABSTRACT: We establish herein conditions for the efficient self-cleaving cyclization of unprotected *N*-acyl urea-linked peptides to form head-to-tail macrocyclic peptides mediated by *N*-terminal cysteine. We report a detailed investigation of the parameters of the reaction, including variation of the reaction conditions, the *N*-terminal residue, the C-terminal residue, the capping protocol, and the macrocycle size. Two sets of optimized conditions are employed in the synthesis of macrocyclic targets ranging from a tetrapeptide to the disulfide-linked 14-mer, sunflow-er trypsin inhibitor 1, and a Gly analog thereof. Under these conditions, no C-terminal epimerization, hydrolysis, or disulfide dimer formation is observed.



<https://pubs.acs.org/doi/abs/10.1021/acs.joc.8b02418>


J. Org. Chem., 2019, 84 (2), pp 1035–1041

ACS Green Chemistry Institute
Pharmaceutical Roundtable

40



Native Chemical Ligation (NCL)



- Coupling of unprotected Peptides, potentially attractive option to produce peptides with cysteine and alanine
- Lack of Green Desulfurization Methodology has limited utility
- Prof. Stockill Awarded Roundtable Research grant extension to develop greener desulfurization methodology



41



Pharmaceutical Roundtable Metrics



Process Mass Intensity Metric



$$\text{Process mass intensity} = \frac{\text{quantity of raw materials input (kg)}}{\text{quantity of bulk API out (kg)}}$$

Where:

Process is all steps of a synthetic path from commonly available materials to the final bulk active pharmaceutical ingredient ("API")

Raw Materials are all materials including water that are used directly in the process of synthesizing, isolating, and purifying the API salt


Bulk API out is the final salt form of the active ingredient that was produced in the synthesis, dried to the expected specification

42




Process Mass Intensity (PMI)

ACS GCI compiled industry waste data for pharmaceutical manufacturing across development and commercial in 2007 and 2008*¹⁻³



Excel PMI calculator
available: acsgcipr.org*²



*1 R. K. Henderson, J. Kindervater and J. B. Manley, *Lessons Learned Through Measuring Green Chemistry Performance – The Pharmaceutical Experience* (2007).

*2 ACS GCI Pharmaceutical Roundtable presentation "Convergent PMI Calculator" (2014).

*3 The PMI data, which exclude solvent and water-intensive biopharmaceutical fermentation processes, were significantly higher in 2008 compared to 2007, possibly due to reassessment of synthesis starting points. We show the 2008 data.

Audience Survey Question

ANSWER THE QUESTION ON BLUE SCREEN IN ONE MOMENT



Which Therapeutic Class generally has the highest Process Mass Intensity (PMI) and generates the most waste?

- Small Molecule
- Oligonucleotide
- Synthetic Peptide
- Recombinant Protein

** If your answer differs greatly from the choices above tell us in the chat!*




Therapeutic Class PMI Data Comparison

- Small molecule PMI ~ 168 (industry average)
- Peptide PMI > 5000 (≥ 40 mer)
- Biopharmaceutical PMI ~7700 (Mabs)
- Oligonucleotide
 - MOE Gapmer PMI ~3300
 - SiRNA PMI ~7000
- Common Starting point are purchased amidites or amino acids



Biologics PMI Data

Overall PMI ~ 7700 kg/kg API




- 14 process data sets covering $\geq 12,000$ L and $\leq 5,000$ L operation volumes for MABS processes
- PMI per amino acid is lower than oligonucleotides and peptides




Oligonucleotide PMI Data

Solvents and Water




Unit Ops



- Avg. PMI ~ 4300 kg/kg API
- Starting point = amidite raw materials
- Acetonitrile is primary process solvent



Chemistry Steps



- 2019 ACS Pharma RT Benchmarking Study

Oligonucleotide by Compound

- No trend with development phase





Improving Sustainability for Oligonucleotide Manufacture

Purification:

- Optimising the purification step, re-purification of mixed fractions?
- Remove the lyophilisation, ship API solution (refrigerated or frozen) or package straight into vials? Reduce cycle time and energy use
- Other isolation techniques, e.g. precipitation
- Reduction of waste in the supply chain
- Can cold chain be solved? -20 °C API storage and shipping adds 10-15% to product costs – common to nearly all large molecules

Alternative Synthetic Approaches:


- Scalable solution phase synthesis via precipitation (Ajinomoto)
- Scalable solution phase synthesis via membrane filtration (Imperial)
- Enzyme catalysed templated ligation
- ACN used exclusively for chemistry steps – replace?
- Molecular Design for Stability - cold chain only if necessary



49



Enzyme Catalyzed Templated Ligation



- Shortmers assemble on a template strand
- Ligase enzyme joins the shortmers together
- Heat to wash off impurities and incomplete intermediates
- Heat further to dissociate the product from the template
- Aqueous based
- Removes the need for a purification step



50



Conclusions

- Significant environmental business case for Green Chemistry and Engineering adoption
- Peptide, Oligonucleotide and Biologics Manufacture in largest need of innovations to improve Environmental Profile.
- The ACS Green Chemistry Institute Pharmaceutical Roundtable provides **leadership and influence** throughout industry and supply chain.
 - Developed powerful set of tools (e.g. solvent selection guide, PMI/LCA calculator, reagent guide, etc.) available to all.
 - Funding of key research priorities as non-profit.
- The ACS Green Chemistry Institute Pharmaceutical Roundtable has evolved its mission since 2005, from exclusive small molecule focus initially to include other modalities in 2019 such as **peptides, proteins and oligonucleotides**.
- Open call for Innovation!



51



ACS GCI Pharma Roundtable: Fall 2019 Meeting in China

Wednesday 18th Sept 2019: Day 1 GCIPR (**Asymchem**)

Thursday 19th Sept 2019: Day 2 GCIPR

Onsite at Asymchem Tianjin

- Roundtable meeting (~100 people)
- Tour of Asymchem green chemistry capabilities

Friday 20th Sept 2019: Day 3 GCIPR (**Pharmaron**)

Onsite at Pharmaron Beijing site (Taihe Road, BDA, Beijing 100176)


- Roundtable meeting (~100 people)
- Tour of Pharmaron site



52



Slimming the Waste-line in Large Molecule Syntheses



Slides available now! Recordings are an exclusive ACS member benefit.

www.acs.org/acswebinars

This ACS Webinar is co-produced with the ACS Green Chemistry Institute

53

Upcoming ACS Webinar

www.acs.org/acswebinars



RECENT DEVELOPMENTS in PATENT LAW

ACS Technical Division Chemistry & the Law (CHAL) | ACS Chemistry for Life

NON-OBVIOUSNESS OF CHEMICAL AND PHARMACEUTICAL FORMULATION PATENTS

▶ **FREE** | Thursday, July 18 at 2pm ET

ACS Webinars

<https://www.acs.org/content/acs/en/acs-webinars/business-entrepreneurship/non-obviousness.html>

54

The ACS Green Chemistry Institute Pharmaceutical Roundtable (ACS GCIPR) Advancing Research!




- The ACS GCIPR has identified key synthetic chemistry and process research challenges whose solutions would result in more efficient pharmaceutical process development and production.

<https://www.acsgcipr.org>

55



Slimming the Waste-line in Large Molecule Syntheses



Slides available now! Recordings are an exclusive ACS member benefit.

www.acs.org/acswwebinars

This ACS Webinar is co-produced with the ACS Green Chemistry Institute

56

How has ACS Webinars[®] benefited you?

CLICK • WATCH • LEARN • DISCUSS



“This ACS Webinar was informative about the benefits of using paper and hazards of plastics. Great to know what strides the paper industry is taking to recycle and the rates of recycling. Very impressive and encouraging!”

Fan of the Week

Jeanne Shoulder
QC Manager, DSM Nutritional Products
ACS member 7 years strong!

Is **paper** and **pulp** recycling the solution to our **single-use** *package problem?*

<https://www.acs.org/content/acs/en/acs-webinars/technology-innovation/paper/video.html>

OPEN ACCESS RECORDING!

Be a featured fan on an upcoming webinar! Write to us @ acswebinars@acs.org

57



ACS Webinars[®]

CLICK • WATCH • LEARN • DISCUSS



@AmericanChemicalSociety



@AmerChemSociety



@AmerChemSociety



<https://www.linkedin.com/company/american-chemical-society>

Contact ACS Webinars[®] at acswebinars@acs.org

58



<http://bit.ly/ACSnewmember>

59



ACS Webinars[®] does not endorse any products or services. The views expressed in this presentation are those of the presenter and do not necessarily reflect the views or policies of the American Chemical Society.



Mike Russell Erik

Contact ACS Webinars[®] at acswebinars@acs.org

60

Upcoming ACS Webinar

www.acs.org/acswebinars

A promotional banner for an ACS webinar. The background is a blue grid with white line drawings of a balance scale and a gavel. The text "RECENT DEVELOPMENTS in PATENT LAW" is written in large, bold, yellow letters. Below this, a yellow bar contains the text "NON-OBVIOUSNESS OF CHEMICAL AND PHARMACEUTICAL FORMULATION PATENTS". At the bottom, there is a red play button icon, the word "FREE", and the date and time "Thursday, July 18 at 2pm ET". The ACS logo and "ACS Webinars" text are also present.

RECENT DEVELOPMENTS
in **PATENT LAW**

NON-OBVIOUSNESS OF CHEMICAL AND PHARMACEUTICAL FORMULATION PATENTS

FREE | Thursday, July 18 at 2pm ET

ACS Technical Division
Chemistry & the Law (CHAL)

ACS
Chemistry for Life®

ACS Webinars
GIVE • WATCH • LEARN • DISCUSS

<https://www.acs.org/content/acs/en/acs-webinars/business-entrepreneurship/non-obviousness.html>

61